APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01
November 03, 2022 03:00 ET
|
invIOs GmbH
Administration of aerosolized APN01 shown to be safe and well tolerated at all dose levels, with no adverse events above Grade 2Investigators recommend further development of inhaled APN01, which may...